Where thiazolidinediones will fit

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Diabetes/Metabolism Research Reviews

• Publication date

  2002-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/dmrr.250PMID 11921436
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Rosiglitazone reduces urinary albumin excretion in type II diabetes

  2003cited by this paper
• Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes.

  2001cited by this paper
• Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group.

  2000cited by this paper
• Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group.

  2000cited by this paper
• Addition of low‐dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients

  2000cited by this paper
• Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with Type II diabetes

  2000cited by this paper
• Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial.

  2000cited by this paper
• Insulin sensitivity in subjects with type 2 diabetes. Relationship to cardiovascular risk factors: the Insulin Resistance Atherosclerosis Study.

  1999cited by this paper
• Thiazolidinediones down-regulate plasminogen activator inhibitor type 1 expression in human vascular endothelial cells: A possible role for PPARgamma in endothelial function.

  1999cited by this paper
• Induction of insulin resistance by glucosamine reduces blood flow but not interstitial levels of either glucose or insulin.

  1999cited by this paper
• The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2001 by The Endocrine Society Rosiglitazone Monotherapy Is Effective in Patients with Type 2 Diabetes

  1999cited by this paper
• Inheritance of a mitochondrial DNA defect and impaired glucose tolerance in BHE/Cdb rats

  1999cited by this paper
• Insulin and Coronary Artery Disease: Is Syndrome X the Unifying Hypothesis?

  1998cited by this paper
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

  1998cited by this paper
• Implications of blood glucose, insulin resistance and beta-cell function in impaired glucose tolerance.

  1998cited by this paper
• Troglitazone in Combination With Sulfonylurea Restores Glycemic Control in Patients With Type 2 Diabetes

  1998cited by this paper
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)

  1998cited by this paper
• Efficacy, safety, and dose-response characteristics of glipizide gastrointestinal therapeutic system on glycemic control and insulin secretion in NIDDM. Results of two multicenter, randomized, placebo-controlled clinical trials. The Glipizide Gastrointestinal Therapeutic System Study Group.

  1997cited by this paper
• Contraindications to Metformin Therapy in Patients With NIDDM

  1997cited by this paper
• Efficacy, Safety, and Dose-Response Characteristics of Glipizide Gastrointestinal Therapeutic System on Glycemic Control and Insulin Secretion in NIDDM: Results of two multicenter, randomized, placebo-controlled clinical trials

  1997cited by this paper
• Rates of hypoglycemia in users of sulfonylureas.

  1997cited by this paper
• The insulin sensitizer, BRL 49653, reduces systemic fatty acid supply and utilization and tissue lipid availability in the rat.

  1997cited by this paper
• Insulin resistance implications for type II diabetes mellitus and coronary heart disease.

  1997cited by this paper
• Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.

  1995cited by this paper
• Repeat Treatment of Obese Mice With BRL 49653, a New Potent Insulin Sensitizer, Enhances Insulin Action in White Adipocytes: Association With Increased Insulin Binding and Cell-Surface GLUT4 as Measured by Photoaffinity Labeling

  1995cited by this paper
• A New Antidiabetic Agent, BRL 49653, Reduces Lipid Availability and Improves Insulin Action and Glucoregulation in the Rat

  1994cited by this paper
• Diabetes, Other Risk Factors, and 12-Yr Cardiovascular Mortality for Men Screened in the Multiple Risk Factor Intervention Trial

  1993cited by this paper
• Intensive Conventional Insulin Therapy for Type II Diabetes: Metabolic effects during a 6-mo outpatient trial

  1993cited by this paper
• Prospective analysis of the insulin-resistance syndrome (syndrome X).

  1992cited by this paper
• The role of free fatty acid metabolism in the pathogenesis of insulin resistance in obesity and noninsulin-dependent diabetes mellitus.

  1991cited by this paper
• Banting lecture 1988. Role of insulin resistance in human disease.

  1988cited by this paper
• Role of Insulin Resistance in Human Disease

  1988cited by this paper
• The Triumvirate: β-Cell, Muscle, Liver: A Collusion Responsible for NIDDM

  1988influential reference
• The Prospective Cardiovascular Münster (PROCAM) study: prevalence of hyperlipidemia in persons with hypertension and/or diabetes mellitus and the relationship to coronary heart disease.

  1988cited by this paper
• Glycemic effects of intensive caloric restriction and isocaloric refeeding in noninsulin-dependent diabetes mellitus.

  1985cited by this paper
• Morbidity and Mortality in Diabetics In the Framingham Population: Sixteen Year Follow-up Study

  1974cited by this paper

• Β-CELL FAILURE AND PRESERVATION IN TYPE 2 DIABETES MELLITUS: A REVIEW

  2016cites this paper
• Role of Adipose Tissue in the Pathogenesis and Treatment of Metabolic Syndrome

  2014cites this paper
• Obesidad en gerontes con síndrome metabólico y factores asociados / Obesity in the elderly having metabolic syndrome and its association to other factors

  2009cites this paper
• Diabetes‐associated macrovasculopathy: pathophysiology and pathogenesis

  2007cites this paper
• S 26948

  2007cites this paper
• Clinical thiazolidinediones as PPARgamma ligands with the potential for the prevention of cardiovascular disease in diabetes.

  2006cites this paper
• Incretin Mimetics: Promising New Therapeutic Options in the Treatment of Type 2 Diabetes

  2005cites this paper
• Rosiglitazone combined with insulin preserves islet β cell function in adult‐onset latent autoimmune diabetes (LADA)

  2005cites this paper
• The Rationale for Early , Aggressive Treatment of Type 2 Diabetes : The Cost Ramifications of Improved Health Outcomes

  2004influential citation
• Pioglitazone is Effective Therapy for Elderly Patients with Type 2 Diabetes Mellitus

  2004cites this paper
• Polycystic ovary syndrome and ovulation induction.

  2003cites this paper
• Current literature in diabetes.

  2002cites this paper
• Current literature in diabetes

  2001cites this paper